The Narcolepsy market growth is driven by factors like increase in the prevalence of Narcolepsy, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Narcolepsy market report also offers comprehensive insights into the Narcolepsy market size, share, Narcolepsy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Narcolepsy market size growth forward.
Some of the key highlights from the Narcolepsy Market Insights Report:
Strategise your business goals by understanding market dynamics @ Narcolepsy Market Landscape
Narcolepsy Overview
Narcolepsy is a rare, chronic neurological disorder characterized by sudden, uncontrollable episodes of sleep. Individuals with narcolepsy experience excessive daytime sleepiness, struggling to stay awake and concentrate throughout the day. They may also have sleep attacks, where they unexpectedly fall asleep without warning. Another symptom is cataplexy, a temporary loss of muscle control that leads to weakness or even collapsing. Cataplexy is often triggered by strong emotions such as laughter or anger. Additionally, people with narcolepsy may have vivid dreams and wake up frequently during the night, with dreams occurring as they fall asleep or upon waking.
The underlying cause of narcolepsy is often a deficiency in hypocretin, a brain chemical that regulates alertness. Due to its rarity and many cases going undiagnosed, the exact prevalence of narcolepsy is difficult to determine. Currently, there is no cure for narcolepsy, but lifestyle changes to improve sleep habits and medication can help minimize the impact of the condition on daily life.
Do you know the treatment paradigms for different countries? Download our Narcolepsy Market Sample Report
Narcolepsy Epidemiology Segmentation
DelveInsight’s Narcolepsy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Narcolepsy historical patient pools and forecasted Narcolepsy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Narcolepsy Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Narcolepsy Epidemiological Insights
Recent Breakthroughs in the Narcolepsy Market:
Narcolepsy Treatment Market
The Narcolepsy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Narcolepsy market trends by analyzing the impact of current Narcolepsy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Narcolepsy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Narcolepsy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Narcolepsy market in 7MM is expected to witness a major change in the study period 2019-2032.
Narcolepsy Therapy Assessment
AXS-12: Axsome therapeutics
AXS-12 (reboxetine) is a norepinephrine reuptake inhibitor that is being developed for the treatment of narcolepsy. It increases wakefulness, maintains muscle tone, and improves cognition by modulating noradrenergic activity. Reboxetine has a long track record of safety in Europe and over 40 countries where it is licensed for the treatment of depression. Positive pre-clinical and Phase 2 clinical data in patients with narcolepsy show that AXS-12 improves daytime drowsiness while decreasing cataplexy (sudden loss of muscle control) in an open-label pilot experiment. AXS-12 has been designated as an Orphan Drug by the US Food and Drug Administration (FDA) for the treatment of narcolepsy. The medication is now being examined in the Phase III development stage.
Narcolepsy Key Companies
Narcolepsy Therapies
For more information, visit Narcolepsy Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Narcolepsy Market Report:
Key Questions Answered in the Narcolepsy Market Report 2032:
Table of Contents:
1 Narcolepsy Market Key Comprehensive Insights
2 Narcolepsy Market Report Introduction
3 Competitive Intelligence Analysis for Narcolepsy
4 Narcolepsy Market Analysis Overview at a Glance
5 Executive Summary of Narcolepsy
6 Narcolepsy Epidemiology and Market Methodology
7 Narcolepsy Epidemiology and Patient Population
8 Narcolepsy Patient Journey
9 Narcolepsy Treatment Algorithm, Narcolepsy Current Treatment, and Medical Practices
10 Key Endpoints in Narcolepsy Clinical Trials
11 Narcolepsy Marketed Therapies
12 Narcolepsy Emerging Therapies
13 Narcolepsy: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Narcolepsy
16 Narcolepsy Market Key Opinion Leaders Reviews
18 Narcolepsy Market Drivers
19 Narcolepsy Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Narcolepsy Epidemiology 2032
DelveInsight’s “Narcolepsy – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Narcolepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Narcolepsy Pipeline 2023
“Narcolepsy Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Narcolepsy market. A detailed picture of the Narcolepsy pipeline landscape is provided, which includes the disease overview and Narcolepsy treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
